Zobrazeno 1 - 10
of 1 326
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia
Publikováno v:
Journal of Clinical Oncology. 41:1809-1815
PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherap
Autor:
Thierry André, David Tougeron, Guillaume Piessen, Christelle de la Fouchardière, Christophe Louvet, Antoine Adenis, Marine Jary, Christophe Tournigand, Thomas Aparicio, Jérôme Desrame, Astrid Lièvre, Marie-Line Garcia-Larnicol, Thomas Pudlarz, Romain Cohen, Salomé Memmi, Dewi Vernerey, Julie Henriques, Jérémie H. Lefevre, Magali Svrcek
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2023, 41 (2), pp.255-265. ⟨10.1200/JCO.22.00686⟩
Journal of Clinical Oncology, 2023, 41 (2), pp.255-265. ⟨10.1200/JCO.22.00686⟩
PURPOSE In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care. Perioperative chemotherapy remains debatable for gastric/GEJ adenocarcinoma wi
Autor:
Anjali S. Advani, Anna Moseley, Kristen M. O'Dwyer, Brent L. Wood, Min Fang, Matthew J. Wieduwilt, Ibrahim Aldoss, Jae H. Park, Rebecca B. Klisovic, Maria R. Baer, Wendy Stock, Rupali R. Bhave, Megan Othus, Richard C. Harvey, Cheryl L. Willman, Mark R. Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba
Publikováno v:
J Clin Oncol
PURPOSE Chemotherapy outcomes in older patients with Philadelphia (Ph) chromosome–negative B-acute lymphoblastic leukemia (ALL) are very poor. Here, we evaluated blinatumomab as induction and consolidation therapy followed by prednisone, vincristin
Autor:
En Cheng, Fang-Shu Ou, Chao Ma, Donna Spiegelman, Sui Zhang, Xin Zhou, Tiffany M. Bainter, Leonard B. Saltz, Donna Niedzwiecki, Robert J. Mayer, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Edward L. Giovannucci, Erin L. Van Blarigan, Justin C. Brown, Kimmie Ng, Cary P. Gross, Jeffrey A. Meyerhardt, Charles S. Fuchs
Publikováno v:
J Clin Oncol
PURPOSE Current tools in predicting survival outcomes for patients with colon cancer predominantly rely on clinical and pathologic characteristics, but increasing evidence suggests that diet and lifestyle habits are associated with patient outcomes a
Autor:
Guofan Xu, Lei Feng, Hun Ju Lee, Michelle Avellaneda, Preetesh Jain, Linghua Wang, Luis Fayad, Omar Moghrabi, L. Jeffrey Medeiros, Cezar Iliescu, Nathan Fowler, Shuangtao Zhao, Yang Liu, Selvi Thirumurthi, Michael L. Wang, Chi Young Ok, Maria Badillo, Lucy Navsaria, Graciela M. Nogueras González, David Santos, Christopher R. Flowers, Francisco Vega, Guilin Tang, Holly Hill, Rashmi Kanagal-Shamanna, Fredrick B. Hagemeister, Yixin Yao
Publikováno v:
J Clin Oncol
PURPOSE Most patients with mantle cell lymphoma (MCL) are older. In this study, we investigated the efficacy and safety of a chemotherapy-free combination with ibrutinib and rituximab (IR) in previously untreated older patients with MCL (age ≥ 65 y
Autor:
Fritz Offner, Karima Amaador, Kazem Nasserinejad, Dries Deeren, Efstathios Kastritis, Steven T. Pals, Willem Kraan, Jeanette K. Doorduijn, Roberto D Liu, Monique C. Minnema, Marcel Kap, Marie José Kersten, Lara H Böhmer, Lidwine W. Tick, Meletios A. Dimopoulos, Josephine M.I. Vos, Martine E D Chamuleau, Maria Gavriatopoulou
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(1), 40-51. American Society of Clinical Oncology
Kersten, M J, Amaador, K, Minnema, M C, Vos, J M I, Nasserinejad, K, Kap, M, Kastritis, E, Gavriatopoulou, M, Kraan, W, Chamuleau, M E D, Deeren, D, Tick, L W, Doorduijn, J K, Offner, F, Böhmer, L H, Liu, R D, Pals, S T & Dimopoulos, M A 2022, ' Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia : Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 1, pp. 40-51 . https://doi.org/10.1200/JCO.21.00105
Journal of clinical oncology, 40(1), 40-51. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(1), 40-51. American Society of Clinical Oncology
Kersten, M J, Amaador, K, Minnema, M C, Vos, J M I, Nasserinejad, K, Kap, M, Kastritis, E, Gavriatopoulou, M, Kraan, W, Chamuleau, M E D, Deeren, D, Tick, L W, Doorduijn, J K, Offner, F, Böhmer, L H, Liu, R D, Pals, S T & Dimopoulos, M A 2022, ' Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia : Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 1, pp. 40-51 . https://doi.org/10.1200/JCO.21.00105
Journal of clinical oncology, 40(1), 40-51. American Society of Clinical Oncology
PURPOSE Proteasome inhibitors are effective in Waldenström's macroglobulinemia (WM) but require parenteral administration and are associated with polyneuropathy. We investigated efficacy and toxicity of the less neurotoxic oral proteasome inhibitor
Autor:
Wierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, Alessandra, Badoux, X. C., Kuss, B. J., Jackson, S., Moreno, Carol, Jacobs, R. M. D., Pagel, J. M., Flinn, I., Pak, Y., Zhou, Cathy, Szafer-Glusman, E., Ninomoto, J., Dean, James P, James, D. F., Ghia, Paolo, Tam, C. S., Universitat Autònoma de Barcelona
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 34
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
PURPOSE CAPTIVATE ( NCT02910583 ), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leuk
Autor:
David Malka, Cedric Lecaille, Anne-Laure Bignon, Nicolas Williet, Caroline Pétorin, Thomas Aparicio, Jérôme Desramé, Jean-Marc Phelip, Côme Lepage, Eric Francois, Yves Rinaldi, Anthony Turpin, Prodige Investigators, Karine Le Malicot, Laetitia Dahan, Jean-François Seitz, Christine Rebischung, Olivier Bouché, Jean-Baptiste Bachet
Publikováno v:
Journal of Clinical Oncology. 39:3242-3250
PURPOSE Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis. Our previous trial (PRODIGE 4—ACCORD 11) demonstrated the superiority of 6-month chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) over